BRCA1 mutations do not increase prostate cancer risk: Results from a meta-analysis including new data

Prostate

Volumn 71, Issue 16, 2011, Pages 1768-1779

  Fachal, Laura ^a   Gõmez Caamaño, Antonio ^b   Celeiro Muñoz, Catuxa ^b   Peleteiro, Paula ^b   Blanco, Ana ^a   Carballo, Ana ^b   Forteza, Jerõnimo ^b   Carracedo, Úngel ^a   Vega, Ana ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

BRCA1; founder mutations; Galicia (NW Spain); meta analysis; prostate cancer

Indexed keywords

BRCA1 PROTEIN;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; GENE MUTATION; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RNA SPLICING; SYSTEMATIC REVIEW;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 80054087237     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21394     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ,. Cancer Statistics, 2008. CA Cancer J Clin 2008; 58 (2): 71-96. (Pubitemid 351521864)
2. Black RJ, Bray F, Ferlay J, Parkin DM,. Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33 (7): 1075-1107. (Pubitemid 27310783)
3. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K,. Environmental and heritable factors in the causation of cancer-Analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343 (2): 78-85. (Pubitemid 30451850)
4. Grönberg H, Damber L, Damber J,. Familial prostate cancer in Sweden. A nationwide register cohort study. Cancer 1996; 77 (1): 138-143. (Pubitemid 26002749)
5. Carter B, Bova G, Beaty T, Steinberg G, Childs B, Isaacs W, Walsh P,. Hereditary prostate cancer: Epidemiologic and clinical features. J Urol 1993; 150 (3): 797-802. (Pubitemid 23241269)
6. Freedman ML,. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci USA 2006; 103: 14068-14073. (Pubitemid 44452981)
7. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Cazier J-B, Sainz J, Jakobsdottir M, Kostic J, Magnusdottir DN, Ghosh S, Agnarsson K, Birgisdottir B, Le Roux L, Olafsdottir A, Blondal T, Andresdottir M, Gretarsdottir OS, Bergthorsson JT, Gudbjartsson D, Gylfason A, Thorleifsson G, Manolescu A, Kristjansson K, Geirsson G, Isaksson H, Douglas J, Johansson J-E, Balter K, Wiklund F, Montie JE, Yu X, Suarez BK, Ober C, Cooney KA, Gronberg H, Catalona WJ, Einarsson GV, Barkardottir RB, Gulcher JR, Kong A, Thorsteinsdottir U, Stefansson K,. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006; 38 (6): 652-658. (Pubitemid 43927306)
8. Schumacher FR, Feigelson HS, Cox DG, Haiman CA, Albanes D, Buring J, Calle EE, Chanock SJ, Colditz GA, Diver WR, Dunning AM, Freedman ML, Gaziano JM, Giovannucci E, Hankinson SE, Hayes RB, Henderson BE, Hoover RN, Kaaks R, Key T, Kolonel LN, Kraft P, Le Marchand L, Ma J, Pike MC, Riboli E, Stampfer MJ, Stram DO, Thomas G, Thun MJ, Travis R, Virtamo J, Andriole G, Gelmann E, Willett WC, Hunter DJ,. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res 2007; 67 (7): 2951-2956. (Pubitemid 46724830)
9. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, Rafnar T, Gudbjartsson D, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Blondal T, Stacey SN, Helgason A, Gunnarsdottir S, Olafsdottir A, Kristinsson KT, Birgisdottir B, Ghosh S, Thorlacius S, Magnusdottir D, Stefansdottir G, Kristjansson K, Bagger Y, Wilensky RL, Reilly MP, Morris AD, Kimber CH, Adeyemo A, Chen Y, Zhou J, So W-Y, Tong PCY, Ng MCY, Hansen T, Andersen G, Borch-Johnsen K, Jorgensen T, Tres A, Fuertes F, Ruiz-Echarri M, Asin L, Saez B, van Boven E, Klaver S, Swinkels DW, Aben KK, Graif T, Cashy J, Suarez BK, van Vierssen Trip O, Frigge ML, Ober C, Hofker MH, Wijmenga C, Christiansen C, Rader DJ, Palmer CNA, Rotimi C, Chan JCN, Pedersen O, Sigurdsson G, Benediktsson R, Jonsson E, Einarsson GV, Mayordomo JI, Catalona WJ, Kiemeney LA, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K,. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007; 39 (8): 977-983. (Pubitemid 47185170)
10. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, Rafnar T, Bergthorsson JT, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Xu J, Blondal T, Kostic J, Sun J, Ghosh S, Stacey SN, Mouy M, Saemundsdottir J, Backman VM, Kristjansson K, Tres A, Partin AW, Albers-Akkers MT, Godino-Ivan Marcos J, Walsh PC, Swinkels DW, Navarrete S, Isaacs SD, Aben KK, Graif T, Cashy J, Ruiz-Echarri M, Wiley KE, Suarez BK, Witjes JA, Frigge M, Ober C, Jonsson E, Einarsson GV, Mayordomo JI, Kiemeney LA, Isaacs WB, Catalona WJ, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K,. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007; 39 (5): 631-637. (Pubitemid 46676102)
11. Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, Waliszewska A, Neubauer J, Tandon A, Schirmer C, McDonald GJ, Greenway SC, Stram DO, Le Marchand L, Kolonel LN, Frasco M, Wong D, Pooler LC, Ardlie K, Oakley-Girvan I, Whittemore AS, Cooney KA, John EM, Ingles SA, Altshuler D, Henderson BE, Reich D,. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007; 39 (5): 638-644. (Pubitemid 46676106)
12. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF, Hoover R, Hunter DJ, Chanock SJ, Thomas G,. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39 (5): 645-649. (Pubitemid 46676108)
13. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA,. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336 (20): 1401-1408. (Pubitemid 27208598)
14. Ford DED, Bishop DT, Narod SA, Goldgar DE,. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343 (8899): 692-695. (Pubitemid 24087847)
15. Thompson D, Easton DF,. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94 (18): 1358-1365. (Pubitemid 35154140)
16. Levy-Lahad E, Friedman E,. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 2007; 96 (1): 11-15. (Pubitemid 46094632)
17. Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, Bhatia J, Stadler Z, Fine SW, Reuter V, Zelefsky M, Morris MJ, Scher HI, Klein RJ, Norton L, Eastham JA, Scardino PT, Robson ME, Offit K,. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010; 16 (7): 2115-2121.
18. Hamel N, Kotar K, Foulkes WD,. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer. BMC Med Genet 2003; 4 (1): 7.
19. Hubert A, Peretz T, Manor O, Kaduri L, Wienberg N, Lerer I, Sagi M, Abeliovich D,. The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet 1999; 65 (3): 921-924. (Pubitemid 30468737)
20. Nastiuk KL, Mansukhani M, Terry MB, Kularatne P, Rubin MA, Melamed J, Gammon MD, Ittmann M, Krolewski JJ,. Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate 1999; 40 (3): 172-177. (Pubitemid 29334865)
21. Vazina A, Baniel J, Yaacobi Y, Shtriker A, Engelstein D, Leibovitz I, Zehavi M, Sidi AA, Ramon Y, Tischler T, Livne PM, Friedman E,. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Br J Cancer 2000; 83 (4): 463-466. (Pubitemid 30487858)
22. Kirchhoff T, Kauff ND, Mitra N, Nafa K, Huang H, Palmer C, Gulati T, Wadsworth E, Donat S, Robson ME, Ellis NA, Offit K,. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 2004; 10 (9): 2918-2921. (Pubitemid 38619665)
23. Agalliu I, Gern R, Leanza S, Burk RD,. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clin Cancer Res 2009; 15 (3): 1112-1120.
24. Cybulski C, Gorski B, Gronwald J, Huzarski T, Byrski T, Debniak T, Jakubowska A, Wokolorczyk D, Gliniewicz B, Sikorski A, Stawicka M, Godlewski D, Kwias Z, Antczak A, Krajka K, Lauer W, Sosnowski M, Sikorska-Radek P, Bar K, Klijer R, Romuald Z, Malkiewicz B, Borkowski A, Borkowski T, Szwiec M, Posmyk M, Narod SA, Lubinski J,. BRCA1 mutations and prostate cancer in Poland. Eur J Cancer Prev 2008; 17 (1): 62-66. (Pubitemid 350307519)
25. Vega A, Campos B, Bressac-de-Paillerets B, Bond PM, Janin N, Douglas FS, Domènech M, Baena M, Pericay C, Alonso C, Carracedo A, Baiget M, Diez O,. The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript. Hum Mutat 2001; 17 (6): 520-521.
26. Vega A, Torres M, Martínez JI, Ruiz-Ponte C, Barros F, Carracedo A,. Analysis of BRCA1 and BRCA2 in breast and breast/ovarian cancer families shows population substructure in the Iberian peninsula. Ann Hum Genet 2002; 66 (1): 29-36.
27. Santos C, Peixoto A, Rocha P, Vega A, Soares M, Cerveira N, Bizarro S, Pinheiro M, Pereira D, Rodrigues H, Castro F, Henrique R, Teixeira M,. Haplotype and quantitative transcript analyses of Portuguese breast/ovarian cancer families with the BRCA1 R71G founder mutation of Galician origin. Familial Cancer 2009; 8 (3): 203-208.
28. Purcell S, Cherny SS, Sham PC,. Genetic Power Calculator: Design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003; 19 (1): 149-150. (Pubitemid 36150192)
29. Greene F, Balch C, Haller D, Morrow M,. AJCC cancer staging manual, 6th edition. New York: Springer; 2002.
30. Langston AA, Stanford JL, Wicklund KG, Thompson JD, Blazej RG, Ostrander EA,. Germ-line BRCA1 mutations in selected men with prostate cancer. Am J Hum Genet 1996; 58 (4): 881-885. (Pubitemid 26086679)
31. Wilkens EP, Freije D, Xu J, Nusskern DR, Suzuki H, Isaacs SD, Wiley K, Bujnovszky P, Meyers DA, Walsh PC, Isaacs WB,. No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer. The Prostate 1999; 39 (4): 280-284. (Pubitemid 29244502)
32. Sinclair CS, Berry R, Schaid D, Thibodeau SN, Couch FJ,. BRCA1 and BRCA2 have a limited role in familial prostate cancer. Cancer Res 2000; 60 (5): 1371-1375. (Pubitemid 30152009)
33. Gayther SA, de Foy KAF, Harrington P, Pharoah P, Dunsmuir WD, Edwards SM, Gillett C, Ardern-Jones A, Dearnaley DP, Easton DF, Ford D, Shearer RJ, Kirby RS, Dowe AL, Kelly J, Stratton MR, Ponder BAJ, Barnes D, Eeles RA,. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 AND BRCA2 in familial prostate cancer. Cancer Res 2000; 60 (16): 4513-4518. (Pubitemid 32103633)
34. Ikonen T, Matikainen MP, Syrjakoski K, Mononen N, Koivisto PA, Rokman A, Seppala EH, Kallioniemi OP, Tammela TLJ, Schleutker J,. BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland. J Med Genet 2003; 40 (8): e98.
35. Liede A, Karlan BY, Narod SA,. Cancer risks for male carriers of germline mutations in BRCA1 or BR.A2: A review of the literature. J Clin Oncol 2004; 22 (4): 735-742. (Pubitemid 41095079)
36. Rosen EM, Fan S, Goldberg ID,. BRCA1 and prostate cancer. Cancer Invest 2001; 19 (4): 396-412. (Pubitemid 32525187)
37. Dong JT,. Prevalent mutations in prostate cancer. J Cell Biochem 2006; 97 (3): 433-447.
38. Douglas JA, Levin AM, Zuhlke KA, Ray AM, Johnson GR, Lange EM, Wood DP, Cooney KA,. Common variation in the BRCA1 gene and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007; 16 (7): 1510-1516. (Pubitemid 47076887)
39. Lehrer S, Fodor F, Stock RG, Stone NN, Eng C, Song HK, McGovern M,. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br J Cancer 1998; 78 (6): 771-773. (Pubitemid 28418311)
40. Giusti RM, Rutter JL, Duray PH, Freedman LS, Konichezky M, Fisher-Fischbein J, Greene MH, Maslansky B, Fischbein A, Gruber SB, Rennert G, Ronchetti RD, Hewitt SM, Struewing JP, Iscovich J,. A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet 2003; 40 (10): 787-792. (Pubitemid 37311080)
41. Niell BL, Rennert G, Bonner JD, Almog R, Tomsho LP, Gruber SB,. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst 2004; 96 (1): 15-21. (Pubitemid 38180955)
42. Thompson D, Easton D,. Consortium tBCL. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 2002; 11 (4): 329-336. (Pubitemid 34408211)
43. Milne RL, Osorio A, Cajal TRy, Vega A, Llort G, de la Hoya M, Diez O, Alonso MC, Lazaro C, Blanco I, Sanchez-de-Abajo A, Caldes T, Blanco A, Grana B, Duran M, Velasco E, Chirivella I, Cardenosa EE, Tejada M-I, Beristain E, Miramar M-D, Calvo M-T, Martinez E, Guillen C, Salazar R, San Roman C, Antoniou AC, Urioste M, Benitez J,. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res 2008; 14: 2861-2869.
44. Roa BB, Boyd AA, Volcik K, Richards CS,. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996; 14 (2): 185-187. (Pubitemid 26338801)
45. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC,. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995; 11 (2): 198-200.